Phaseline

Companies › Shanghai Hengrui Pharmaceutical

Shanghai Hengrui Pharmaceutical: clinical trials, targets and expected readouts

15 active drug programs in 34 registered trials: 25 Phase 1, 7 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SHR-A2102 for Injection
unclear - Shanghai Hengrui proprietary compound
–Phase 3Advanced Urothelial Carcinoma; Advanced Solid Tumors; Non-small Cell Lung Cancer; Advanced or Metastatic Non-small Cell Lung CancerMay 2027
SHR-A1904
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Cancer; CLDN18.2-positive Advanced Solid TumorSep 2027
SHR-7787 Injection–Phase 2Limited-stage Small-cell Lung Cancer; Malignant Solid Tumors; Advanced Solid TumorsDec 2026
Adebrelimab (SHR-1316)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 2Limited-stage Small-cell Lung Cancer; Malignant Solid Tumors; Advanced or Metastatic Non-small Cell Lung Cancer; Locally Advanced or Metastatic Pancreatic Cancer With …Oct 2027
BP102 Injection–Phase 2Malignant Solid TumorsDec 2028
HRS8807–Phase 1ER-Positive, HER2-Negative Breast CancerDec 2026
SHR6390
CDK4/6 inhibitor
CDK4, CDK6Phase 1ER-Positive, HER2-Negative Breast CancerDec 2026
SHR-2005–Phase 1Intermediate and High-risk Non-muscle Invasive Bladder CancerDec 2026
SHR-1501
KRAS inhibitor
–Phase 1High-risk NMIBC; Patients With Advanced or Metastatic Malignant TumorsMay 2027
HRS-4642–Phase 1Locally Advanced or Metastatic Pancreatic Cancer WithOct 2027
SHR-7367 Injection–Phase 1Solid TumorDec 2027
SHR-3836–Phase 1Multiple MyelomaApr 2028
SHR-9839 for Injection–Phase 1Advanced Solid Tumor; Advanced Solid TumorsJun 2029
SHR-A1921 for Injection–Phase 1Advanced Solid TumorsJun 2029
SHR-A2009 for Injection–Phase 1Advanced Solid TumorsJun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05701709SHR-A2102 for InjectionPhase 1Advanced Solid TumorsOncologyAug 2025
NCT04877717SHR-A1904Phase 1Advanced Solid CancerOncologyDec 2025
NCT05836948SHR-9839 for InjectionPhase 1Advanced Solid TumorOncologyMay 2026
NCT06512051Adebrelimab (SHR-1316)Phase 1Advanced or Metastatic Non-small Cell Lung CancerOncologyOct 2026
NCT06512051SHR-A2102 for InjectionPhase 1Advanced or Metastatic Non-small Cell Lung CancerOncologyOct 2026
NCT06605222SHR-7787 InjectionPhase 1Advanced Solid TumorsOncologyDec 2026
NCT04993430HRS8807Phase 1ER-Positive, HER2-Negative Breast CancerOncologyDec 2026
NCT04993430SHR6390Phase 1ER-Positive, HER2-Negative Breast CancerOncologyDec 2026
NCT06108492SHR-2005Phase 1Intermediate and High-risk Non-muscle Invasive Bladder CancerOncologyDec 2026
NCT05410730SHR-1501Phase 1High-risk NMIBCOncologyMay 2027
NCT06639347SHR-A2102 for InjectionPhase 1Advanced Urothelial CarcinomaOncologyMay 2027
NCT06738251SHR-A2102 for InjectionPhase 3Advanced Urothelial CarcinomaOncologySep 2027
NCT06649292SHR-A1904Phase 3Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaOncologySep 2027
NCT07296341Adebrelimab (SHR-1316)Phase 1Locally Advanced or Metastatic Pancreatic Cancer WithOncologyOct 2027
NCT07296341HRS-4642Phase 1Locally Advanced or Metastatic Pancreatic Cancer WithOncologyOct 2027
NCT07229586Adebrelimab (SHR-1316)Phase 1Solid TumorOncologyDec 2027
NCT07073534Adebrelimab (SHR-1316)Phase 1Patients With Advanced or Metastatic Malignant TumorsOncologyDec 2027
NCT07073534SHR-1501Phase 1Patients With Advanced or Metastatic Malignant TumorsOncologyDec 2027
NCT07229586SHR-7367 InjectionPhase 1Solid TumorOncologyDec 2027
NCT06350006SHR-A1904Phase 1CLDN18.2-positive Advanced Solid TumorOncologyDec 2027
NCT06350006Adebrelimab (SHR-1316)Phase 1CLDN18.2-positive Advanced Solid TumorOncologyDec 2027
NCT07490613SHR-3836Phase 1Multiple MyelomaOncologyApr 2028
NCT07798947SHR-7787 InjectionPhase 2Limited-stage Small-cell Lung CancerOncologyDec 2028
NCT07268040SHR-7787 InjectionPhase 2Malignant Solid TumorsOncologyDec 2028
NCT07798947Adebrelimab (SHR-1316)Phase 2Limited-stage Small-cell Lung CancerOncologyDec 2028
NCT07268040Adebrelimab (SHR-1316)Phase 2Malignant Solid TumorsOncologyDec 2028
NCT06895928SHR-A2102 for InjectionPhase 2Advanced Solid TumorsOncologyDec 2028
NCT07268040BP102 InjectionPhase 2Malignant Solid TumorsOncologyDec 2028
NCT06474455Adebrelimab (SHR-1316)Phase 1Advanced Solid TumorsOncologyJun 2029
NCT06474455SHR-9839 for InjectionPhase 1Advanced Solid TumorsOncologyJun 2029
NCT06474455SHR-A1921 for InjectionPhase 1Advanced Solid TumorsOncologyJun 2029
NCT06474455SHR-A2009 for InjectionPhase 1Advanced Solid TumorsOncologyJun 2029
NCT07229729SHR-A2102 for InjectionPhase 2Non-small Cell Lung CancerOncologyOct 2029
NCT06417554SHR-A2102 for InjectionPhase 1Advanced Solid TumorsOncologyDec 2031

Targets

CLDN18 (1) CD274 (1) CDK4 (1) CDK6 (1)

Companies with the same targets

Pfizer AstraZeneca Astellas Shanghai Chia Tai Tianqing Pharmaceutical Technology Development IO Biotech Novartis Pharmacosmos Eli Lilly Jiangsu HengRui Medicine Shandong Suncadia Medicine

Companies built like this

Jiangsu Simcere Pharmaceutical Sichuan Kelun-Biotech Biopharmaceutical Shandong Suncadia Medicine Shenyang Sunshine Pharmaceutical Sichuan Baili Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.